【火热】山东药企拿下暴涨8475%潜力品种

米内网
25 Apr

近日,国家药监局官网显示,山东新华制药申报的3类仿制药——盐酸美金刚口服溶液、普瑞巴林口服溶液同日获批生产并视同过评,均为口服溶液剂。米内网数据显示,2023年中国三大终端六大市场(统计范围详见本文末)口服液体剂(化学药)销售额超过400亿元。普瑞巴林口服溶液、盐酸美金刚口服溶液同属于神经系统药物,均为口服溶液剂,且均已纳入全国医保乙类目录。普瑞巴林口服溶液用于治疗带状疱疹后神经痛、纤维肌痛,也可...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10